Overview

Evaluation of Clinical Equivalence Between Two Lubiprostone Products

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the clinical equivalence and safety of the Test formulation of lubiprostone 24 mcg capsules compared to the marketed formulation AMITIZA® (lubiprostone) 24 mcg capsules (Sucampo Pharmaceuticals, Inc.) in patients with confirmed chronic idiopathic constipation.
Phase:
Phase 3
Details
Lead Sponsor:
Anchen Pharmaceuticals, Inc
Collaborator:
Novum Pharmaceutical Research Services
Treatments:
Lubiprostone